semaglutide patent expiration semaglutide patent expiry date us As the patents on semaglutide, a popular diabetes and anti-obesity drug Massive Rs 50,000 Cr Opportunity
Description
The MHRA has updated its GLP-1 guidance due to a risk of the rare occurence of NAION among semaglutide patients
GLP-1 GLP-1/GIP 2022 FDA 2 Mounjaro 2023 FDA Zepbound ...
i think so
GLP-1 medications, also known as glucagon-like peptide-1 receptor agonists, are a powerful tool for managing type 2 diabetes
The general recommendation for a sample size to assess the safety of a weight-reduction drug is 3,000 subjects randomized to the investigational drug within the to-be258 recommended dosage range and no fewer than 1,500 subjects randomized to placebo for at least 1 year of treatment at the maintenance dosage Multiple #obesitytrials have successfully used flexible dosing regimens
Hot take: GLP-1 spend doesnt have to break the budget So what are large employers missing
